COVID-19 Testing Information: Learn more


MI Express Care offers the FDA-EUA monoclonal antibody infusion to help reduce the risk of hospitalization in high-risk individuals who test positive for COVID-19. Infusions are available by appointment only and require a virtual visit with one of our providers.


Book an appointment

Our Convenient Locations

Canton Location

MI Express Urgent Care

44237 Michigan Ave, Canton, MI 48188

Monday - Friday : 9 AM - 7 PM
Saturday - Sunday : 10 AM - 6 PM

Ann Arbor Location

MI Express Urgent Care

80 S Zeeb Rd Unit 101 C, Ann Arbor, MI 48103

Monday - Friday : 9 AM - 8 PM
Saturday - Sunday : 10 AM - 6 PM

Criteria for administration of Monoclonal Antibody Treatment

  • High Risk Individuals
  • The following medical conditions or other factors may place adults and pediatric patients (age 12-17 years and weighing at least 40 kg) at higher risk for progression to severe COVID-19. We will only administer to adults in our clinic.
  • Older age (for example, age ≥65 years of age)
  • Obesity or being overweight (for example, BMI >25 kg/m2 , or if age 12-17, have BMI ≥85th percentile for their age and gender based on CDC growth charts. Generally given the limitation in supply we will give to the higher risk of BMI > 30
  • Pregnancy (must discuss do not know what occurs to the fetus and risk of complications/possible teratogenicity is unknown at this time)
  • Chronic kidney disease stage 3 or worse
  • Diabetes
  • Immunosuppressive disease or immunosuppressive treatment
  • Cardiovascular disease (including congenital heart disease) or hypertension
  • Chronic lung diseases (for example, chronic obstructive pulmonary disease, asthma [moderate-to severe], interstitial lung disease, cystic fibrosis and pulmonary hypertension)
  • Sickle cell disease
  • Neurodevelopmental disorders (for example, cerebral palsy) or other conditions that confer medical complexity (for example, genetic or metabolic syndromes and severe congenital anomalies)
  • Having a medical-related technological dependence (for example, tracheostomy, gastrostomy, or positive pressure ventilation (not related to COVID-19)
  • Priority will be given to unvaccinated or undervaccinated, which means those not up to date include those who are not vaccinated, have not completed their initial series i.e. 2 doses of Pfizer/Moderna or 1 dose of J & J. If past 5 months from primary series of vaccination with Pfizer or Moderna then should have a booster or considered as not up to date. Those with J & J, should have booster 2 months after primary vaccination to be considered up to date.

    FDA Emergency Use Authorization only allows for one MAB currently which is Bebtelovimab.

      Bebtelovimab is authorized for use under Emergency Use Authorization (EUA) for the treatment of mild-to-moderate coronavirus disease 2019 (COVID-19) in adults and pediatric patients (12 years of age and older weighing at least 40 kg):
    • with positive results of direct SARS-CoV-2 viral testing, and
    • who are at high risk for progression to severe COVID-19, including hospitalization or death, and
    • for whom alternate COVID-19 treatment options approved or authorized by FDA are not accessible or clinically appropriate.

About bebtelovimab

Bebtelovimab (LY-CoV1404; LY3853113) is a neutralizing IgG1 monoclonal antibody (mAb) directed against the spike protein of SARS-CoV-2 that maintains binding and neutralizing activity across currently known and reported variants of concern, including Omicron and BA.2. Bebtelovimab is being studied for the treatment of mild-to-moderate COVID-19 both as a monotherapy and together with other mAbs. Lilly has licensed and developed bebtelovimab after it was discovered by AbCellera and the scientists at the National Institute of Allergy and Infectious Diseases (NIAID) Vaccine Research Center.

Bebtelovimab is not authorized for use in patients who:
  • are hospitalized due to COVID-19, OR
  • require oxygen therapy and/or respiratory support due to COVID-19, OR
  • require an increase in baseline oxygen flow rate and/or respiratory support due to COVID-19 and are on chronic oxygen therapy and/or respiratory support due to underlying non-COVID-19 related comorbidity.
Treatment with bebtelovimab has not been studied in patients hospitalized due to COVID-19. Monoclonal antibodies, such as bebtelovimab, may be associated with worse clinical outcomes when administered to hospitalized patients with COVID-19 requiring high flow oxygen or mechanical ventilation.
What Is Monoclonal Antibody

What Is Monoclonal Antibody Therapy?

Monoclonal antibodies are developed in a lab and function similarly to your body’s inherent naturally occurring antibodies. Monoclonal antibodies are administered intravenously to high-risk COVID-19 patients diagnosed with the early stages of the disease. Generally, the infusion decreases risk of progression of COVID-19 from mild and moderate disease to severe disease by a 3-4X relative risk reduction.

How Does Monoclonal Antibody Treatment Work Against

How Does Monoclonal Antibody Treatment Work Against COVID-19?

This treatment is generally used to decrease viral loads and reduce symptom severity in high-risk COVID-19 patients. Monoclonal antibodies can detect and target the spike protein found on the outer part of the COVID-19 virus. This reduces the virus’s ability to attach itself and enter human cells. Generally, it has been proven to boost our immune system and help it fight off the novel coronavirus. It also helps decrease the risk of being hospitalized.

Book MAB Appointment!

Book Your MAB Infusion Appointment!


Per CDC, if you have been treated with a monoclonal antibody infusion, you should not get a COVID-19 vaccination within 90 days of your infusion.

Please refer to our criteria section to see if you are eligible. If you are unsure, you may fill out our form and our team will assess your eligibility.

Side effects are rare but may include infusion reactions such as nausea, vomiting, diarrhea, fever, headache, chills, wheezing or coughing, decreased blood pressure, skin swelling, rashes, throat irritation, muscle pain/ache, itching, weakness, and dizziness. Inform your doctor immediately if you feel any of these symptoms after the infusion.

Whether or not you have received monoclonal antibody therapy, you need to be isolated if you have tested positive for COVID-19.

As of January 20th, 2022 – Blue Cross PPO and Medicare are providing coverage. However, please check with your insurance provider to see if you can receive the infusion at no cost to you.

Call Us Hold Your Spot